• Males or females aged 18 years or older (≥18 years).

• Patients diagnosed with pathologically confirmed advanced solid tumors.

• Subjects have at least one target lesion as assessed per the RECIST 1.1.

• Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 1 and no deterioration within 2 weeks before the first dose.

• Have a life expectancy of at least 12 weeks.

• Female subjects of childbearing potential are willing to take appropriate contraceptive measures and should not breastfeed from signing the informed consent until 6 months after the last dose; male subjects must agree to use barrier contraception (i.e. condoms) from signing the informed consent to 6 months after the last dose.

• Female subjects must have a negative pregnancy test within 7 days prior to the first dose (for subjects with tumor related abnormal elevation of human chorionic gonadotropin \[HCG\], an ultrasound of uterus and appendages should be performed within 7 days prior to the first dose to rule out pregnancy), or demonstrate no risk for pregnancy.

• Subject must be voluntarily enrolled in this clinical trial, be able to understand the study procedures and to sign written informed consent.